Chelating frameworks based on hydroxymethylene phosphine (HMP) functionalit
ies provides a novel approach to produce chelate-conjugates compatible with
development of new Tc-99m and Re-186/188 radiopharmaceuticals. Studies wit
h a bombesin conjugate demonstrates the potential of using HMP-based chelat
ing frameworks to develop radiolabeled receptor-avid agents for targeting c
ancers.